Effects of different doses of oral Cholecalciferol on serum 25-OHD,PTH, Calcium,and bone markers during Fall and Winter in school children of Taleghan

Evaluation of the effects of monthly and bimonthly consumption of 50 000 units of oral vitamin D3 on serum levels of 25-OHD, iPTH, calcium and other bone markers and comparison of the results with placebo group in 210 healthy school children of Taleghan

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT138711231681N1

Enrollment

210

Registered

2010-08-25

Start date

2007-07-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Status of vitamin D in school children. Vitamin D deficiency, unspecified

Interventions

Intervention 1: 50 000 units of oral vitamin D3 monthly during 6 months. Intervention 2: Placebo monthly, similar to the real drug in shape for 6 months. Intervention 3: 50 000 units of oral vitamin D

Treatment - Drugs

Placebo

50 000 units of oral vitamin D3 monthly during 6 months.

Placebo monthly, similar to the real drug in shape for 6 months

50 000 units of oral vitamin D3 bimonthly during 6 months.

Eligibility

Sex/Gender

All

Age

14 Years to 20 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: All healthy active students. Exclusion criteria: Those with disorders affecting bone metabolism or taking supplements or drugs affecting bone metabolism.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Serum levels of 25-OHD. Timepoint: at the begining, middle, and end of the study. Method of measurement: RIA.	—

Secondary

Measure	Time frame
Serum levels of bone specific alkaline phosphatase. Timepoint: At the beginning, middle, and the end of the study. Method of measurement: RIA.;Serum levels of osteocalcin. Timepoint: samples were taken at the begining, middle, and end of the study. Method of measurement: RIA.;Serum levels of Calcium. Timepoint: At the beginning, middle, and the end of the study. Method of measurement: RIA.;Serum levels of iPTH. Timepoint: At the beginning, middle, and the end of the study. Method of measurement: RIA.;24 hour urine c-telopeptide. Timepoint: At the beginning, middle, and the end of the study. Method of measurement: RIA.	—

Measure

Time frame

Serum levels of bone specific alkaline phosphatase. Timepoint: At the beginning, middle, and the end of the study. Method of measurement: RIA.;Serum levels of osteocalcin. Timepoint: samples were taken at the begining, middle, and end of the study. Method of measurement: RIA.;Serum levels of Calcium. Timepoint: At the beginning, middle, and the end of the study. Method of measurement: RIA.;Serum levels of iPTH. Timepoint: At the beginning, middle, and the end of the study. Method of measurement: RIA.;24 hour urine c-telopeptide. Timepoint: At the beginning, middle, and the end of the study. Method of measurement: RIA.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli A.M.Ghazi MD

Shahid Beheshti University of Medical Sciences

ghazi@endocrine.ac.ir+98 21 2240 9309

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026